Loading...
In the large NIH-funded GAIT study of osteoarthritic knee pain, glucosamine, chondroitin sulfate (CS), or both was no better than placebo in relieving pain or slowing the progression of joint-space narrowing (JW Feb 28 2006 and JW Oct 16 2008). Now, researchers present the results of another CS study, which was sponsored by the manufacturer of a prescription preparation that is available in Europe.
A total of 622 patients with knee osteoarthritis were randomized to receive daily CS (800 mg) or placebo. During 2 years of follow-up, narrowing of medial tibiofemoral joint space was significantly less in the CS group than in the placebo group; the difference between groups became even greater during the second year of the study. Pain scores were…